CytomX Therapeutics Inc (CTMX) Gagner

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 69 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.